Fresh analysis reveals that people who stop using new slimming jabs like Wegovy and Mounjaro tend to recover lost weight at a significantly accelerated pace than those who end traditional lifestyle regimens.
Research printed in a major medical journal demonstrates that while overweight people can lose substantial amounts of their total mass while on the medication, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"People purchasing such treatments need to be aware of the risk of fast rebound weight gain when the therapy ends," stated researcher Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment weight in about one and a half years.
Comparing Treatments
The analysis, which looked at dozens of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
The team emphasize that people who shed pounds through lifestyle changes alone usually have a more gradual creep back—around 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Experts propose the mode of action of the injections explains the accelerated regain.
The injections mimic a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of the hormone concentrations several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating far more likely."
A Lifelong Issue?
Medical guidelines recommend the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts contend that, due to the high risk of weight regain, the therapy might need to be life-long.
This view is supported by pharmaceutical companies, who say that the results "highlight the persistent character of excess weight," comparing it to managing diseases like high blood pressure.
Patient Accounts
Users who have discontinued the jabs describe a intense resurgence of hunger.
"I experienced a switch activating and I was suddenly starving," described one woman.
This challenge is compounded if patients have not adopted lasting dietary or behavioural changes during treatment.
Significant Adoption
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Use is more common among females than men.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic solution and lasting health benefits relies on ongoing behavioural management.
